<DOC>
	<DOCNO>NCT00239291</DOCNO>
	<brief_summary>To estimate safety tolerability 250 mg ZD1839 give concurrently 3D-CRT patient non-metastatic prostate cancer</brief_summary>
	<brief_title>Safety Study Explore Combination Gefitinib ( ZD1839 , Iressa ) Radiotherapy Non-Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Biopsy confirmation localise ( T2 ) locally advanced ( T3 ) prostate cancer PSA 20 ng/mL Lymph node negative Nonmetastatic Written inform consent Well differentiate stage T2 prostate cancer ( Gleason score 2 4 ) Distant nodal metastasis Prostatectomy Concomitant LHRH analog treatment Previous concomitant antiandrogens Active ILD</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>